Clostridium botulinum and the clinical laboratorian: A detailed review of botulism, including biological warfare ramifications of botulinum toxin

Archives of Pathology and Laboratory Medicine

Volumn 128, Issue 6, 2004, Pages 653-662

  Caya, James G ^a,b   Agni, Rashmi ^a   Miller, Joan E ^a  

^a University of Wisconsin Health   (United States)

^b Medical Assessment and Consultation SC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN;

BIOLOGICAL WARFARE; BOTULISM; CLINICAL FEATURE; CLOSTRIDIUM BOTULINUM; DIAGNOSTIC APPROACH ROUTE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DOCUMENT EXAMINATION; HUMAN; INFORMATION RETRIEVAL; LABORATORY TEST; MEDICAL INFORMATION; MEDICAL LITERATURE; PATIENT MONITORING; REVIEW; CLASSIFICATION; DIAGNOSIS, MEASUREMENT AND ANALYSIS; IMMUNOLOGY; ISOLATION AND PURIFICATION; PROGNOSIS; SAFETY;

BIOLOGICAL WARFARE; BOTULINUM TOXINS; BOTULISM; CLINICAL LABORATORY TECHNIQUES; CLOSTRIDIUM BOTULINUM; HUMANS; PROGNOSIS; SAFETY;

EID: 4844230030     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Dunbar EM. Editorial: botulism. J Infect. 1990;20:1-3.
2. Erbguth FJ. Botulinum toxin: a historical note. Lancet. 1998;351:1320.
3. van Ermengem E. Ueber einen neuen anaeroben Bacillus und seine Beziehungen zum Botulismus. Z Hyg Infektionskrankheit. 1897;26:1-56.
4. Sifton DW, ed. Physicians Desk Reference. Montvale, NJ: Thomson PDR; 2003:548-554.
5. Hallett M. One man's poison: clinical applications of botulinum toxin. N Eng J Med. 1999;341:118-120.
6. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve. 1997;57(suppl 6):S146-S168.
7. Gill DM. Bacterial toxins: a table of lethal amounts. Microbiol Rev. 1982;46:86-94.
8. Lacy D, Tepp W, Cohen A, et al. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol. 1998;5:898-902.
9. Hatheway CL. Clostridium botulinum. In: Gorbach SL, ed. Infectious Diseases. 2nd ed. Philadelphia, Pa: WB Saunders Co; 1998:1919-1925.
10. Dolman CE, Iida H. Type E botulism: its epidemiology, prevention and Specific treatment. Can J Public Health. 1963;54:293-308.
11. Popoff MR. Ecology of neurotoxigenic strains of clostridia. Curr Top Microbiol Immunol. 1995;195:1-29.
12. Whittaker RL, Gilbertson RB, Garrett AS. Botulism, type E. Ann Int Med. 1964;61:448-454.
13. Prevot AR, Terrasse J, Daumail J, et al. Existence en France du botulisme humain de type C. Bull Acad Natl Med Paris. 1955;139:355-358.
14. Demarchi J, Mourgues C, Orio J, Prevot AR. Existence du botulisme humain de Type D. Bull Acad Natl Med Paris. 1958;142:580-582.
15. Moller V, Scheibel I. Preliminary report on the isolation of an apparently new type of Clostridium botulinum. Acta Pathol Microbiol Scand. 1960;48:80.
16. Dolman CE, Murakami L. Clostridium botulinum type F with recent observations on other types. J Infect Dis. 1961;109:107-128.
17. Green J, Spear H, Brinson RR. Human botulism (type F): a rare type. Am J Med. 1983;75:893-895.
18. Midura TF, Nygaard GS, Wood RM, Bodily HL. Clostridium botulinum type F: isolation from venison jerky. Appl Microbiol. 1972;24:165-167.
19. Sonnabend O, Sonnabend W, Heinzle R, et al. Isolation of Clostridium botulinum type G and identification of type G botulinal toxin in humans: report of five sudden unexpected deaths. J Infect Dis. 1981;143:22-27.
20. McCroskey LM, Hatheway CL, Woodruff BA, Greenberg JA, Jurgenson P. Type F botulism due to neurotoxigenic Clostridium baratii from an unknown source in an adult. J Clin Microbiol. 1991;29:2618-2620.
21. Meng X, Karasawa T, Zou K, Kuang X, et al. Characterization of a neurotoxigenic Clostridium butyricum strain isolated from the food implicated in an outbreak of food-borne type E botulism. J Clin Microbiol. 1997;35:2160-2162.
22. Crane JK. Preformed bacterial toxins: botulism. Clin Lab Med. 1999;19:583-589.
23. Aureli P, Fenicia L, Pasolini B, et al. Two cases of type E infant botulism caused by neurotoxigenic Clostridium butyricum in Italy. J Infect Dis. 1986;154:207-211.
24. Hall JD, McCroskey LM, Pincomb BJ, Hatheway CL. Isolation of an organism resembling Clostridium baratii which produces type F botulinal toxin from an infant with botulism. J Clin Microbiol. 1985;21:654-655.
25. McCroskey LM, Hatheway CL, Fenicia L, Pasolini B, Aureli P. Characterization of an organism that produces type E botulinal toxin but resembles Clostridium butyricum from the feces of an infant with type E botulism. J Clin Microbiol. 1986;23:201-202.
26. Harvey SM, Sturgeon J, Dassey DE. Botulism due to Clostridium baratii type F toxin. J Clin Microbiol. 2002;40:2260-2262.
27. Suen JC, Hatheway CL, Steigerwalt AG, Brenner DJ. Genetic confirmation of identities of neurotoxigenic Clostridium baratii and Clostridium butyricum implicated as agents of infant botulism. J Clin Microbiol. 1988;26:2191-2192.
28. McCroskey LM, Hatheway CL, Woodruff BA, Greenberg JA, Jurgenson P. Type F botulism due to neurotoxigenic Clostridium baratii from an unknown source in an adult. J Clin Microbiol. 1991;29:2618-2620.
29. Paisley JW, Lauer BA, Arnon SS. A second case of infant botulism type F caused by Clostridium baratii. Pediatr Infect Dis J. 1995;14:912-914.
30. Chaudhry R, Dhawan B, Kumar D, et al. Outbreak of suspected Clostridium butyricum botulism in India. Emerg Infect Dis. 1998;4:506-507.
31. Suen JC, Hatheway CL, Steigerwalt AG, Brenner DJ. Clostridium argentinense sp. nov.: a genetically homogeneous group composed of all strains of Clostridium botulinum toxin type G and some nontoxigenic strains previously identified as Clostridium subterminale or Clostridium hastiforme. Int J Syst Bacteriol. 1988;38:375-381.
32. Allen SD, Emery CL, Siders JA. Clostridium. In: Murray PR, ed-in-chief. Manual of Clinical Microbiology. 7th ed. Washington, DC: American Society for Microbiology; 1999:658-659.
33. Wictome M, Shone CC. Botulinum neurotoxins: mode of action and detection. J Appl Microbiol Symp Suppl. 1998;84:87S-97S.
34. Maselli RA. Pathogenesis of human botulism. Ann N Y Acad Sci. 1998;841:122-139.
35. Smith LDS. Clostridium botulinum: characteristics and occurrence. Rev Inf Dis. 1979;1:637-639.
36. Centers for Disease Control and Prevention. Botulism in the United States 1899-1996: Handbook for Epidemiologists, Clinicians and Laboratory Workers. Atlanta, Ga: Centers for Disease Control and Prevention; 1998.
37. Cherington M. Clinical spectrum of botulism. Muscle Nerve. 1998;21:701-710.
38. Hatheway CL. Botulism: the present status of the disease. Curr Top Microbiol Immunol. 1995;195:55-75.
39. Centers for Disease Control and Prevention. Reported cases of notifiable diseases, by geographic division and area: United States, 2002 (botulism). MMWR Morbid Mortal Wkly Rep. 2003;52:742.
40. Arnon SS, Midura TF, Clay SA, Wood RM, Chin J. Infant botulism: epidemiological, clinical and laboratory aspects. JAMA. 1977;237:1946-1951.
41. Midura TF. Update: infant botulism. Clin Microbiol Rev. 1996;9:119-125.
42. Thompson JA, Glasgow LA, Warpinski JR, Olson C. Infant botulism: clinical spectrum and epidemiology. Pediatrics. 1980;66:936-942.
43. Wigginton JM, Thill P. Infant botulism: a review of the literature. Clin Pediatr. 1993;32:669-674.
44. Wilson R, Morris JG, Snyder JD, Feldman RA. Clinical characteristics of infant botulism in the United States: a study of the non-California cases. Pediatr Infect Dis J. 1982;1:148-150.
45. Hikes DC, Manoli A. Wound botulism. J Trauma. 1981;21:68-71.
46. Merson MH, Dowell VR. Epidemiologic, clinical, and laboratory aspects of wound botulism. N Engl J Med. 1973;289:1005-1010.
47. Passaro DJ, Werner SB, McGee J. Wound botulism associated with black tar heroin among injecting drug users. JAMA. 1998;279:859-863.
48. Griffin PM, Hatheway CL, Rosenbaum RB. Endogenous antibody production to botulinum toxin in an adult with intestinal colonization botulism and underlying Crohn's disease. J Infect Dis. 1997;175:633-637.
49. Bakheit AMO, Ward CD, McLellan DL. Generalized botulism-like syndrome after intramuscular injections of botulism toxin type A: a report of two cases. J Neurol Neurosurg Psychiatry. 1997;62:198.
50. Holzer VE. Botulism from inhalation. Med Klin (Germany). 1962;57:1735-1738.
51. Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon. In: Henderson DA, Inglesby TV, O'Toole T, eds. Bioterrorism Guidelines for Medical and Public Health Management. Chicago, Ill: AMA Press; 2002:141-165.
52. Cherington M. Treatment of botulism and wound botulism. In: Balows A, Dehaan RM, Dowell VR, Guze LB, eds. Anaerobic Bacteria: Role in Disease. Springfield, Ill: CC Thomas Co; 1974:287-294.
53. Donadio JA, Gangarosa EJ, Faich GA. Diagnosis and treatment of botulism. J Infect Dis. 1971;124:108-112.
54. Caya JG. Clostridium botulinum and the ophthalmologist: a review of botulism, including biological warfare ramifications of botulinum toxin. Surv Ophthalmol. 2001;46:25-34.
55. Goode GB, Shearn DL. Botulism: a case with associated sensory abnormalities. Arch Neurol. 1982;39:55.
56. Martinez-Castrillo JC, DelReal MA, Hernandez-Gonzalez A, DeBlas G, Alvarez-Cermeno JC. Botulism with sensory symptoms: a second case. J Neurol Neurosurg Psychiatry. 1991;54:844-845.
57. Roblot P, Roblot F, Fauchere JL, et al. Retrospective study of 108 cases of botulism in Portiers, France. J Med Microbiol. 1994;40:379-384.
58. Ying S, Shuyan C. Botulism in China. Rev Infect Dis. 1986;8:984-990.
59. Centers for Disease Control and Prevention. Outbreak of botulism type E associated with eating a beached whale: western Alaska. MMWR Morbid Mortal Wkly Rep. 2003;52:24-26.
60. Sanders AB, Seifert S, Kobernick M. Botulism. J Fam Pract. 1983;16:987-1000.
61. Dowell VR, McCroskey LM, Hatheway CL, Lombard GL, Hughes JM, Merson MH. Copro-examination for botulinal toxin and Clostridium botulinum: a new procedure for laboratory diagnosis of botulism. JAMA. 1977;238:1829-1832.
62. Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: a clinical and epidemiologic review. Ann Int Med. 1998;129:221-228.
63. Cherington M. Electrophysiologic methods as an aid in diagnosis of botulism: a review. Muscle Nerve. 1982;5:528-529.
64. Centers for Disease Control and Prevention. New telephone number to report botulism cases and request antitoxin. MMWR Morbid Mortal Wkly Rep. 2003;52:774.
65. Allen SD, Emery CL, Siders JA. Clostridium. In: Murray PR, ed-in-chief. Manual of Clinical Microbiology. 7th ed. Washington, DC: American Society for Microbiology; 1999:660-666.
66. Notermans SHW, Wokke JMJ, Van der berg LM. Botulism and Guillain-Barré syndrome. Lancet. 1992;340:303.
67. Hatheway CL, Ferreira JL. Detection and identification of Clostridium botulinum neurotoxins. In: Singh BR, Tu AT, eds. Natural Toxins II. New York, NY: Plenum Press; 1996:481-498.
68. Wictome M, Newton KA, Jameson K, et al. Development of in vitro assays for the detection of botulinum toxins in foods. FEMS Immunol Med Microbiol. 1999;24:319-323.
69. Rodriguez A, Defulian M. Rapid identification of Clostridium botulinum and botulinal toxin in food. Folia Microbiol. 1997;42:149-151.
70. Hallis B, James BAF, Shone CC. Development of novel assays for botulinum type A and B neurotoxins based on their endopeptidase activities. J Clin Microbiol. 1996;34:1934-1938.
71. Singh BR, Silvia MA. Detection of botulinum neurotoxins using optical fiber based biosensors. In: Singh BR, Tu AT, eds. Natural Toxins II. New York, NY: Plenum Press; 1996:499-508.
72. Doellgast GJ, Beard GA, Bottoms JD, et al. Enzyme-linked immunosorbent assay and enzyme-linked coagulation assay for detection of Clostridium botulinum neurotoxins A, B, and E and solution-phase complexes with dual label antibodies. J Clin Microbiol. 1994;32:105-111.
73. Doellgast GJ, Triscott MX, Beard GA, et al. Sensitive enzyme-linked immunosorbent assay for detection of Clostridium botulinum neurotoxins A, B, and E using signal amplification via enzyme-linked coagulation assay. J Clin Microbiol. 1993;31:2402-2409.
74. Doellgast GJ, Brown JE, Koufman JA, Hatheway CL. Sensitive assay for measurement of antibodies to Clostridium botulinum neurotoxins A, B and E: use of hapten-labeled-antibody elution to isolate specific complexes. J Clin Microbiol. 1997;35:578-583.
75. Doellgast CJ, Triscott MX, Beard GA, Bottoms JD. Enzyme-linked immunosorbent assay-enzyme-linked coagulation assay for detection of antibodies to Clostridium botulinum neurotoxins A, B, and E and solution-phase complexes. J Clin Microbiol. 1994;32:851-853.
76. Committee on Infectious Diseases of the American Academy of Pediatrics. In: 1997 Red Book. 24th ed. Elk Grove Village, Ill: American Academy of Pediatrics; 1997:174-176.
77. Critchley EMR, Mitchell JD. Human botulism. Br J Hosp Med. 1990;43:290-292.
78. Black RE, Gunn RA. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med. 1980;69:567-570.
79. Centers for Disease Control and Prevention. Infant botulism: New York City, 2001-2002. MMWR Morbid Mortal Wkly Rep. 2003;52:21-24.
80. Tacket CO, Shandera WX, Mann JM, Hargrett NT, Blake PA. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med. 1984;76:794-798.
81. Edwards RC, Butt FYS, Bonacci CA, Kendall KA. Wound botulism: a clinical experience. Otolaryngol Head Neck Surg. 1997;117(suppl):S214-S218.
82. Franz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA. 1997;278:399-411.
83. Hatheway CL, Dang C. Immunogenicity of the neurotoxins of Clostridium botulinum. In: Jankovic J, Hallett M, eds. Therapy With Botulinum Toxin. New York, NY: Marcel Dekker; 1994:93-107.
84. Middlebrook JL, Brown JE. Immunodiagnosis and immunotherapy of tetanus and botulinum neurotoxins. Curr Top Microbiol Immunol. 1995;195:89-122.
85. Jortani SA, Snyder JW, Valdes R. The role of the clinical laboratory in bioterrorism. Clin Chem. 2000;46:1883-1893.
86. Richmond J, McKinney RW. Biosafety in Microbiological and Biomedical Laboratories. 4th ed. Washington, DC: US Government Printing Office; 1999.
87. Madsen JM. Toxins as weapons of mass destruction: a comparison and contrast with biological warfare and chemical warfare agents. Clin Lab Med. 2001;21:593-605.
88. Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001;235:1059-1070.
89. Shapiro RL, Hatheway C, Becher J, Swerdlow DL. Botulism surveillance and emergency response: a public health strategy for a global challenge. JAMA. 1997;278:433-435.
90. Zilinskas RA. Iraq's biological weapons: the past as future? JAMA. 1999;278:418-424.
91. Beneson AS. Control of communicable diseases. In: Control of Communicable Diseases in Man. 15th ed. Washington, DC: American Public Health Association; 1990:61-66.
92. Franz DR, Pitt LM, Clayton MA, Hanes MA, Rose KJ. Efficacy of prophylactic and therapeutic administration of antitoxin for inhalation botulism. In: Das Gupta B, ed. Botulinum and Tetanus Neurotoxins and Biomedical Aspects. New York, NY: Plenum Press; 1993:473-476.
93. Middlebrook JL. Contributions of the US Army to botulinum toxin research. In: Das Gupta B, ed. Botulinum and Tetanus Neurotoxins and Biomedical Aspects. New York, NY: Plenum Press; 1993:515-519.
94. Gilchrist MJR, McKinney WP, Miller JM, Weisfeld AS. In: Laboratory Safety, Management and Diagnosis of Biological Agents Associated With Bioterrorism: Cumitech 33: Cumulative Techniques and Procedures in Clinical Microbiology. Washington, DC: American Society for Microbiology; 2000.
95. Christopher GW, Cieslak TJ, Pavlin JA, Eitzen EM. Biological warfare: a historical perspective. JAMA. 1997;278:412-417.
96. Danzig R, Berkowsky PB. Why should we be concerned about biological warfare? JAMA. 1997;278:431-432.
97. Holloway HC, Norwood AE, Fullerton CS, Engel CC, Ursano RJ. The threat of biological weapons: prophylaxis and mitigation of psychological and social consequences. JAMA. 1997;278:425-427.
98. Simon JD. Biological terrorism: preparing to meet the threat. JAMA. 1997;278:428-430.
99. Klietmann WF, Ruoff KL. Bioterrorism: implications for the clinical microbiologist. Clin Microbiol Rev. 2001;14:364-381.
100. Sewell DL. Laboratory safety practices associated with potential agents of biocrime or bioterrorism. J Clin Microbiol. 2003;41:2801-2809.